‘Off the shelf’ stem cell firm to benefit from in-house facility, says analyst – OutSourcing-Pharma.com
OutSourcing-Pharma.com |
'Off the shelf' stem cell firm to benefit from in-house facility, says analyst
OutSourcing-Pharma.com The analyst firm was also positive about Reneuron's CTX stem cell line platform which is being used to develop 'off‐the‐shelf' stem cell treatments for large patient population diseases. The cell line is produced from a single tissue sample and offers … |
